TARSATampa Area Recreational Scheduling Association (Florida)
TARSATransportes Angela Rosa S. A. (Argentina)
TARSATratamiento Anti-Retroviral Sumamente Activo (Spanish: Highly Active Anti-Retroviral Treatment)
References in periodicals archive ?
We are pleased that the FDA has accepted our NDA for review, offering the possibility that TBRIA could be cleared for marketing in 2016," said David Brand, President and CEO of TARSA.
TARSA has exclusive development and worldwide commercialization rights to the oral calcitonin product developed with Enteris' technology, with the current exception of China.
About TARSA Therapeutics TARSA is developing TBRIA(TM), a novel oral formulation of calcitonin for the treatment of postmenopausal osteoporosis in women greater than five years post menopause when alternative treatments are not suitable.